当前位置: 首页 >> 检索结果
共有 4324 条符合本次的查询结果, 用时 1.8977472 秒

3821. A Pseudo-Gastric Bubble.

作者: Yi-Ning Lo.;Juei-Seng Wu.;Hsueh-Chien Chiang.
来源: Gastroenterology. 2023年165卷1期e16-e18页

3822. Prognostic significance of the Naples prognostic score in colorectal cancer patients undergoing curative resection: a propensity score matching analysis.

作者: Atsushi Sugimoto.;Tatsunari Fukuoka.;Masatsune Shibutani.;Hiroaki Kasashima.;Kishu Kitayama.;Masaichi Ohira.;Kiyoshi Maeda.
来源: BMC Gastroenterol. 2023年23卷1期88页
Systemic inflammation is recognized as a hallmark of cancer that contributes to tumor development and progression in various malignancies. The Naples prognostic score (NPS) was established as a prognostic indicator for colorectal cancer (CRC). This study aims to examine the predictive value of the NPS for survival in CRC patients undergoing curative resection by a propensity score matching (PSM) analysis.

3823. Comparison of surgery rates in biologic-naïve patients with Crohn's disease treated with vedolizumab or ustekinumab: findings from SOJOURN.

作者: Michelle Vu.;Sabyasachi Ghosh.;Kandavadivu Umashankar.;Laura Weber.;Christina Landis.;Ninfa Candela.;Benjamin Chastek.
来源: BMC Gastroenterol. 2023年23卷1期87页
Crohn's disease (CD) is a chronic inflammatory bowel disease characterized by relapsing and remitting inflammation that leads to progressive bowel damage. Despite advances in medical treatment for CD, many patients require surgical intervention. Most studies of surgery rates are from patients treated with anti-tumor necrosis factor alpha (anti-TNFα) treatments, with comparatively little data on the surgery rates of patients treated with vedolizumab and ustekinumab. SOJOURN aimed to estimate the hazard rate and incidence of the first CD-related surgery following initiation of treatment with vedolizumab or ustekinumab in biologic-naïve patients with CD.

3824. Sox9, A Key Regulator of Gastric Stem Cell Behavior Driving Cancer Initiation.

作者: Hui Yi Grace Lim.;Nick Barker.
来源: Gastroenterology. 2023年164卷7期1052-1053页

3825. An Unusual Cause of Acute Cholecystitis.

作者: Ping-Hung Ko.;Chih-Wei Tseng.
来源: Gastroenterology. 2023年165卷4期e4-e5页

3826. An Unusual Finding on Computed Tomography in a Patient With Iron-Deficiency Anemia.

作者: Hailong Zhang.;Jiahao Fan.;Qingliang Zhu.
来源: Gastroenterology. 2023年165卷4期e6-e9页

3827. An Unusual Case of Anal Pain With Intense Metabolic Activity of the Internal Anal Sphincter.

作者: Riccardo Caccia.;Massimo Castellani.;Guido Basilisco.
来源: Gastroenterology. 2023年165卷1期30-33页

3828. Whether the Golgi protein 73 could be a diagnostic serological marker in hepatocellular carcinoma: a meta analysis.

作者: Xu Zhang.;Li-Na Wu.;Xiao-Qing Li.;Xia Luo.;Shui-Wei Liu.;Le Zhang.;Shah Nawaz.;Li-Na Ma.;Xiang-Chun Ding.
来源: BMC Gastroenterol. 2023年23卷1期85页
The Value of Golgi protein 73 (GP73) in the diagnosis of Hepatocellular carcinoma (HCC) remains controversial, especially in its differentiation between HCC and cirrhosis. Besides, some papers showed that GP73 levels are correlated with liver fibrosis. This study conducts a meta-analysis to evaluate the value of GP73 in diagnosing HCC and differential diagnosing HCC from liver cirrhosis.

3829. A novel nomogram to predict 90-day mortality in patients with hepatitis B virus-related acute-on-chronic liver failure: a single-center retrospective study.

作者: Ye Xiong.;Zuoxun Xia.;Lu Yang.;Jianrong Huang.
来源: BMC Gastroenterol. 2023年23卷1期86页
Acute-on-chronic liver failure (ACLF) is a critical illness with high mortality. Herein, we developed and validated a new and simple prognostic nomogram to predict 90-day mortality in hepatitis B virus-related ACLF (HBV-ACLF) patients.

3830. Behavioral abnormalities in C57BL/6 mice with chronic ulcerative colitis induced by DSS.

作者: Yuxin Zhou.;Gang Ji.;Xiaoyi Yang.;Zhenhua Chen.;Liangliang Zhou.
来源: BMC Gastroenterol. 2023年23卷1期84页
Clinical epidemiological studies have found that some patients with ulcerative colitis (UC) are prone to mental disorders. DSS-induced acute and chronic UC models are often used to evaluate the efficacy of anti-UC drugs. However, whether DSS has an effect on mouse behavior has not been reported.

3831. Eubiotic effect of rifaximin is associated with decreasing abdominal pain in symptomatic uncomplicated diverticular disease: results from an observational cohort study.

作者: Vladimir Ivashkin.;Oleg Shifrin.;Roman Maslennikov.;Elena Poluektova.;Alexander Korolev.;Anna Kudryavtseva.;George Krasnov.;Nona Benuni.;Giovanni Barbara.
来源: BMC Gastroenterol. 2023年23卷1期82页
Rifaximin effectively treats symptomatic uncomplicated diverticular disease (SUDD) and has shown eubiotic potential (i.e., an increase in resident microbial elements with potential beneficial effects) in other diseases. This study investigated changes in the fecal microbiome of patients with SUDD after repeated monthly treatment with rifaximin and the association of these changes with the severity of abdominal pain.

3832. Determining the survival benefit of postoperative radiotherapy in patients with pT1-3N1M0 rectal cancer undergoing total mesorectal excision: a retrospective analysis.

作者: Jin-Hu Chen.;Qing Ye.;Feng Huang.
来源: BMC Gastroenterol. 2023年23卷1期83页
The National Comprehensive Cancer Network guidelines recommend routine postoperative adjuvant radiotherapy and chemotherapy for patients with stage III rectal cancer who do not receive neoadjuvant therapy before surgery. The present study aimed to evaluate the value of postoperative radiotherapy in patients with low-risk disease (pT1-3N1M0) who did not receive neoadjuvant therapy prior to total mesorectal excision.

3834. Improving the Experiences of Sexual and Gender Minority-Identifying Trainees in Gastroenterology and Hepatology.

作者: Alexander Goldowsky.;Julia Ding.;Christopher Vélez.;Sonali Paul.
来源: Gastroenterology. 2023年164卷4期510-514页

3835. Impact of comorbidities on hospital mortality in patients with acute pancreatitis: a population-based study of 110,021 patients.

作者: Nils Jimmy Hidalgo.;Elizabeth Pando.;Rodrigo Mata.;Nair Fernandes.;Sara Villasante.;Marta Barros.;Daniel Herms.;Laia Blanco.;Joaquim Balsells.;Ramon Charco.
来源: BMC Gastroenterol. 2023年23卷1期81页
The impact of pre-existing comorbidities on acute pancreatitis (AP) mortality is not clearly defined. Our study aims to determine the trend in AP hospital mortality and the role of comorbidities as a predictor of hospital mortality.

3836. Next-Generation Farnesoid X Receptor Agonists in NASH Treatment: Are We There Yet?

作者: Brian J DeBosch.
来源: Gastroenterology. 2023年165卷2期513-514页

3837. Randomized Trial of Facilitated Adherence to Screening Colonoscopy vs Sequential Fecal-Based Blood Test.

作者: Ann G Zauber.;Sidney J Winawer.;Michael J O'Brien.;Glenn M Mills.;John I Allen.;Andrew D Feld.;Paul A Jordan.;Martin Fleisher.;Irene Orlow.;Reinier G S Meester.;Iris Lansdorp-Vogelaar.;Carolyn M Rutter.;Amy B Knudsen.;Margaret Mandelson.;Aasma Shaukat.;Robin B Mendelsohn.;Anne I Hahn.;Stephanie M Lobaugh.;Brittany Soto Palmer.;Victoria Serrano.;Julie R Kumar.;Sara E Fischer.;Jennifer C Chen.;Sharon Bayuga-Miller.;Deborah Kuk.;Kelli O'Connell.;Timothy R Church.
来源: Gastroenterology. 2023年165卷1期252-266页
Colorectal cancer (CRC) screening guidelines include screening colonoscopy and sequential high-sensitivity fecal occult blood testing (HSgFOBT), with expectation of similar effectiveness based on the assumption of similar high adherence. However, adherence to screening colonoscopy compared with sequential HSgFOBT has not been reported. In this randomized clinical trial, we assessed adherence and pathology findings for a single screening colonoscopy vs sequential and nonsequential HSgFOBTs.

3838. Glepaglutide, a novel glucagon-like peptide-2 agonist, has anti-inflammatory and mucosal regenerative effects in an experimental model of inflammatory bowel disease in rats.

作者: Jolanta Skarbaliene.;Jesper Mosolff Mathiesen.;Bjarne Due Larsen.;Christian Thorkildsen.;Yvette Miata Petersen.
来源: BMC Gastroenterol. 2023年23卷1期79页
Glucagon-like peptide-2 (GLP-2) enhances intestinal repair and attenuates inflammation in preclinical inflammatory bowel disease (IBD) models, making GLP-2 analogues attractive candidates for IBD therapy. Glepaglutide is a long-acting GLP-2 receptor agonist in clinical development for treatment of short bowel syndrome. Here, we investigated if glepaglutide is therapeutically beneficial in rats with small intestinal inflammation.

3839. The prognostic role of the AST/ALT ratio in hepatocellular carcinoma patients receiving thermal ablation combined with simultaneous TACE.

作者: Feihang Wang.;Shanshan Gao.;Mengfei Wu.;Danyang Zhao.;Huiyi Sun.;Sothea Yav.;Yi Chen.;Zihan Zhang.;Minjie Yang.;Yi Dong.;Jianhua Wang.;Xiaolin Wang.;Zhiping Yan.;Lingxiao Liu.
来源: BMC Gastroenterol. 2023年23卷1期80页
To evaluate the prognostic value of the pre-treatment aspartate transaminase (AST)/alanine transaminase (ALT) ratio in hepatocellular carcinoma (HCC) patients receiving radiofrequency ablation (RFA)/microwave ablation (MWA) combined with simultaneous TACE.

3840. Association between intestinal microflora and obesity.

作者: Maryana Savytska.;Marko Kozyk.;Kateryna Strubchevska.;Kateryna Yosypenko.;Tetyana Falalyeyeva.;Nazarii Kobyliak.;Luigi Boccuto.;Rinaldo Pellicano.;Sharmila Fagoonee.;Emidio Scarpellini.;Ludovico Abenavoli.
来源: Minerva Gastroenterol (Torino). 2024年70卷3期342-352页
Obesity has become one of modern society's most serious health problems. Studies from the last 30 years revealed a direct relationship between imbalanced energy intake and increased healthcare costs related to the treatment or management of obesity. Recent research has highlighted significant effects of gut microbial composition on obesity. We aimed to report the current knowledge on the definition, composition, and functions of intestinal microbiota. We have performed an extensive review of the literature searching for the following key words: metabolism, gut microbiota, dysbiosis, and obesity. There is evidence that an association between intestinal microbiota and obesity exists at any age. There are complex genetic, metabolic, and inflammatory mechanisms involved in the pathogenesis of obesity. Revision of indications for use of probiotics, prebiotics, and antibiotics in obese patients should be considered. Microbial composition of the gut may be an important factor involved in the development of obesity. Changes in the gut microbiota may result in changes in human metabolism and weight loss.
共有 4324 条符合本次的查询结果, 用时 1.8977472 秒